FDA approves surgery-sparing immunotherapy for rectal cancer

The FDA has granted accelerated approval to an immunotherapy that may spare some patients with locally advanced rectal cancer from undergoing chemotherapy, radiation and surgery. The approval covers London-based GSK’s dostarlimab-gxly — sold under the brand name Jemperli — as a standalone treatment for adults with previously untreated stage 2 or 3 locally advanced rectal […] The post FDA approves surgery-sparing immunotherapy for rectal cancer appeared first on Becker's Hospital...